Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor. Oral janus kinase inhibitors (JAKi) represent a novel therapeutic class of targeted therapy to treat moderate-to-seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Michelle, Berman-Rosa, Melissa, Ghazawi, Feras M., Bourcier, Marc, Fiorillo, Loretta, Gooderham, Melinda, Guenther, Lyn, Hanna, Sameh, Hong, H. Chih-Ho, Landells, Ian, Lansang, Perla, Marcoux, Danielle, Wiseman, Marni C., Yeung, Jensen, Lynde, Charles, Litvinov, Ivan V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440866/
https://www.ncbi.nlm.nih.gov/pubmed/34540860
http://dx.doi.org/10.3389/fmed.2021.682547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440866/
https://www.ncbi.nlm.nih.gov/pubmed/34540860
http://dx.doi.org/10.3389/fmed.2021.682547

Ejemplares similares